Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy
STUDIO CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, designed and conducted by the ECOG-ACRIN Cancer Research Group…
Read the full articleYou might also wanna read
Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy
STUDIO CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, des
Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders ...
Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, designed and conducted by the ECOG-ACRIN Cancer Research G
Stopping myeloma maintenance after two years shows no survival loss in trial
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance ha
Extended myeloma maintenance therapy shows no additional survival benefit
A major national cooperative group clinical trial led by Mayo Clinic researchers found that continuing maintenance therapy with lenalidomide
Mayo Clinic-Led Study Finds No Improvement in Overall Survival From Longer Multiple Myeloma Maintenance Therapy
A major national cooperative group clinical trial led by Mayo Clinic researchers found that continuing maintenance therapy with lenalidomide
Trial Questions Continuous Maintenance in Newly Diagnosed Myeloma
(MedPage Today) -- Maintenance therapy with continuous lenalidomide (Revlimid) did not significantly improve overall survival (OS) in patien
Comments
Sign in to join the conversation.
No comments yet. Be the first.